DRUG DISCOVERY TRANSFORMATION CONSORTIUM
The Drug Discovery Transformation Consortium is focused on establishing an evidence-based understanding of drug discovery efficiency and effectiveness.
It provides participating companies with:
- a means of exploring the cause and effect of different strategic approaches and practices to drug discovery
- a discussion forum through which they can debate, challenge and, in a culture of collaboration, explore interpretations of the emerging analyses
- a vehicle to gain access to reliable and comparable industry performance metrics of drug discovery, all the way through to ‘clinical proof of concept’
Each participating company will receive the exclusive Key Performance Metrics Report, providing company-specific drug discovery productivity analyses, and Success Rates Report, providing between-phase drug discovery success rates at the target, project and active-substance level. Focused surveys are undertaken to address critical areas of interest, such as the use of biomarkers.